Kidney Cancer - Pipeline Review, Q1 2011
Global Markets Direct’s, 'Kidney Cancer - Pipeline Review, Q1 2011', provides an overview of the Kidney Cancer therapeutic pipeline. This report provides information on the therapeutic development for Kidney Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Kidney Cancer. 'Kidney Cancer - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
- A snapshot of the global therapeutic scenario for Kidney Cancer.
- A review of the Kidney Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Kidney Cancer pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Kidney Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
Kidney Cancer - Pipeline Review, Q1 2011 Reference Code: GMDHC431IDB Publication Date: January 2011 Kidney Cancer – Pipeline Review, Q1 2011 GMDHC431IDB / Pub JAN 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1) Kidney Cancer – Pipeline Review, Q1 2011 Ta b le o f Co n te n ts Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Kidney Cancer Overview 11 Therapeutics Development 12 An Overview of Pipeline Products for Kidney Cancer 12 Kidney Cancer Therapeutics under Development by Companies 14 Kidney Cancer Therapeutics under Investigation by Universities/Institutes 18 Late Stage Products 27 Comparative Analysis 27 Mid Clinical Stage Products 28 Comparative Analysis 28 Early Clinical Stage Products 29 Comparative Analysis 29 Discovery and Pre-Clinical Stage Products 30 Comparative Analysis 30 Companies Involved in Kidney Cancer Therapeutics Development 31 Bristol-Myers Squibb Company 31 Genzyme Corporation 31 Johnson & Johnson 32 F. Hoffmann-La Roche Ltd. 32 Kyowa Hakko Kirin Co., Ltd. 33 Abbott Laboratories 33 Amgen Inc. 34 AstraZeneca PLC 34 Eli Lilly and Company 35 GlaxoSmithKline plc 35 Merck & Co., Inc. 36 Oxford BioMedica plc 36 Takeda Pharmaceutical Company Limited 37 Light Sciences Oncology, Inc. 37 Prolexys Pharmaceuticals, Inc. 38 Neurocrine Biosciences, Inc. 38 ZIOPHARM Oncology, Inc. 39 Novartis AG 39 Astellas Pharma Inc. 40 Eisai Co., Ltd. 40 Pfizer Inc. 41 Exelixis, Inc. 41 VasGene Therapeutics, Inc. 42 Celgene Corporation 42 Bayer AG 43 3SBio Inc. 43 Celldex Therapeutics, Inc. 44 Active Biotech AB 44 Kidney Cancer – Pipeline Review, Q1 2011 GMDHC431IDB / Pub JAN 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2) Kidney Cancer – Pipeline Review, Q1 2011 AEterna Zentaris Inc. 45 Northwest Biotherapeutics, Inc. 45 Cleveland BioLabs, Inc. 46 Oncothyreon Inc 46 Patrys Limited 47 ARQULE, INC 47 Dendreon Corporation 48 Thallion Pharmaceuticals Inc. 48 Antisoma plc 49 TapImmune Inc. 49 OncoTherapy Science, Inc. 50 Innate Pharma SA 50 Protox Therapeutics Inc. 51 Wilex AG 51 Memorial Sloan Kettering Cancer Center 52 Antisoma Research Limited 53 Glycotope GmbH 53 ERYtech Pharma 53 immatics biotechnologies GmbH 54 Curacyte AG 54 AgrenVec, S.L. 55 Gene Signal International SA. 55 MacroGenics, Inc. 56 Pivotal BioSciences, Inc. 56 Neotropix, Inc. 57 Jennerex Biotherapeutics, Inc. 57 Intarcia Therapeutics, Inc. 58 Endocyte, Inc. 58 Pharminox Limited 59 Syndax Pharmaceuticals, Inc. 59 OncoMune, LLC 60 Esperance Pharmaceuticals, Inc. 60 Welichem Biotech Inc. 61 Tigris Pharmaceuticals, Inc. 61 KAHR medical Ltd. 62 Advanced Cancer Therapeutics 62 Medical Enzymes AG 63 Polaris Group 63 IkerChem S.L. 63 Theradex Systems, Inc. 64 Agennix AG 64 Immunovative Therapies, Ltd. 65 Hoosier Oncology Group, Inc. 65 Universities/Institutes Involved in Kidney Cancer Therapeutics Development 66 Kidney Cancer Therapeutics Assessment 87 Assessment by Monotherapy Products 87 Assessment by Combination Products 88 Assessment by Route of Administration 89 Kidney Cancer – Pipeline Review, Q1 2011 GMDHC431IDB / Pub JAN 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(3) Kidney Cancer – Pipeline Review, Q1 2011 Assessment by Molecule Type 91 Late Stage Drug Profiles – Companies 93 ANYARA - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 ANYARA + Interferon Alpha - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 Avastin + Roferon - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 Axitinib - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 Interferon Alfa + CCI-779 - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 NuLeusin - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 Rencarex - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 Tivozanib - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 TroVax + IL-2 - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 Late Stage Drug Profiles – Universities/Institutes 103 Aldesleukin + Interferon - Drug Profile 103 Product Description 103 Mechanism of Action 103 R&D Progress 103 aldesleukin + recombinant interferon alfa + fluorouracil - Drug Profile 105 Product Description 105 Mechanism of Action 105 R&D Progress 106 Aldesleukin for Kidney Cancer - Drug Profile 107 Kidney Cancer – Pipeline Review, Q1 2011 GMDHC431IDB / Pub JAN 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(4) Kidney Cancer – Pipeline Review, Q1 2011 Product Description 107 Mechanism of Action 107 R&D Progress 107 bevacizumab + recombinant interferon alfa - Drug Profile 108 Product Description 108 Mechanism of Action 108 R&D Progress 108 Cisplatin + Gemcitabine + Paclitaxel - Drug Profile 109 Product Description 109 Mechanism of Action 109 R&D Progress 109 Dactinomycin + Carboplatin + Cyclophosphamide + Doxorubicin hydrochloride + Etoposide + Vincristine sulfate - Drug Profile 111 Product Description 111 Mechanism of Action 111 R&D Progress 112 dactinomycin + doxorubicin + vincristine + radiation therapy - Drug Profile 113 Product Description 113 Mechanism of Action 113 R&D Progress 113 Dactinomycin + Filgrastim + Cylophosphamide + Doxorubicin hydrochloride + Etoposide + Vincristine sulfate + Radiation therapy - Drug Profile 114 Product Description 114 Mechanism of Action 114 R&D Progress 115 Doxorubicin hydrochloride - Drug Profile 117 Product Description 117 Mechanism of Action 117 R&D Progress 117 Everolimus - Drug Profile 118 Product Description 118 Mechanism of Action 118 R&D Progress 118 Everolimus + Bevacizumab - Drug Profile 119 Product Description 119 Mechanism of Action 119 R&D Progress 119 Interferon-alpha + Interleukin-2 + 5-Fluorouracil - Drug Profile 120 Product Description 120 Mechanism of Action 120 R&D Progress 120 Pegylated interferon alfa - Drug Profile 122 Product Description 122 Mechanism of Action 122 R&D Progress 122 Recombinant interferon alfa + Isotretinoin - Drug Profile 123 Product Description 123 Mechanism of Action 123 R&D Progress 123 recombinant interferon alfa + thalidomide - Drug Profile 124 Kidney Cancer – Pipeline Review, Q1 2011 GMDHC431IDB / Pub JAN 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(5) Kidney Cancer – Pipeline Review, Q1 2011 Product Description 124 Mechanism of Action 124 R&D Progress 124 Sorafenib - Drug Profile 126 Product Description 126 Mechanism of Action 126 R&D Progress 126 Sorafenib - Drug Profile 127 Product Description 127 Mechanism of Action 127 R&D Progress 127 Sorafenib Tosylate - Drug Profile 129 Product Description 129 Mechanism of Action 129 R&D Progress 129 sorafenib tosylate, sunitinib malate - Drug Profile 130 Product Description 130 Mechanism of Action 130 R&D Progress 130 Sunitinib - Drug Profile 132 Product Description 132 Mechanism of Action 132 R&D Progress 132 sunitinib - Drug Profile 133 Product Description 133 Mechanism of Action 133 R&D Progress 133 Discontinued Products 134 Kidney Cancer - Featured News 135 Oct 14, 2010: Oxford BioMedica Announces Publication Of TroVax Phase III Results In Metastatic Renal Cancer In Clinical Cancer Research 135 Oct 07, 2010: Bayer And Onyx Announce Nexavar Data Presentations At 35th European Society For Medical Oncology Congress 135 Sep 01, 2010: Agensys Initiates Phase I Clinical Trial Of AGS-16M8F For Renal Cancer 136 Aug 12, 2010: AVEO Achieves Enrollment Target Ahead Of Schedule For Pivotal Phase III Trial Of Tivozanib 137 Aug 10, 2010: GenSpera Receives Additional Patent For Oncology Drug, G-202 138 Jul 12, 2010: Threshold Presents Preclinical Results On TH-302 At AACR Translational Cancer Medicine Meeting 138 Jun 05, 2010: Immatics Announces Phase II Results With Its Therapeutic Cancer Vaccine IMA901 in Patients with Advanced Renal Cell Carcinoma at ASCO 139
Pages to are hidden for
"Kidney Cancer - Pipeline Review, Q1 2011"Please download to view full document